SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): COVID-19 adjuvanted vaccine,CpG 1018

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Dynavax Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 23, 2020

            Details:

            The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Silmitasertib

            Therapeutic Area: Infections and Infectious Diseases Product Name: CX 4945

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            The latest international study led by Professor Nevan Krogan of UCSF's Quantitative Biosciences Institute found that the Casein Kinase 2 (CK2) inhibitor, Silmitasertib, displayed robust antiviral activity in treating COVID-19, in vitro.